In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

In May, the German group that pioneered the treatment in rheumatic disease reported on a troubling syndrome they dubbed ...

Objective To estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs associated with HZ among adults with systemic lupus erythematosus ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE). The drug’s ...

During the Phase IIb study (NCT05688696), 187 patients with SLE were randomised to receive 48 weeks of treatment with either 75mg or 50mg orelabrutinib or placebo. Within the 48-week treatment window, ...

Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...

Background Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric systemic lupus ...